Overview

Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)

Status:
Not yet recruiting

Trial end date:
2026-09-30

Target enrollment:

Participant gender:

Summary

In this study, patients with metastatic non-small cell lung cancer that is EGFR-mutated, who have received at least 8 and not more than 12 weeks of treatment with osimertinib without demonstrating disease progression, will receive APL-101 in combination with osimertinib until progression. Dosing of APL-101 will be escalated until the maximum tolerated dose is determined, at which point 10 additional patients will be enrolled at that dose in the expansion cohort.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Washington University School of Medicine

Collaborator:

Apollomics Inc.

Treatments:

Osimertinib